Research ArticleArticle
Open Access
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR)
John K. Botson, John R.P. Tesser, Ralph Bennett, Howard M. Kenney, Paul M. Peloso, Katie Obermeyer, Brian LaMoreaux, Michael E. Weinblatt and Jeff Peterson
The Journal of Rheumatology September 2020, jrheum.200460; DOI: https://doi.org/10.3899/jrheum.200460
John K. Botson
This work was supported by Horizon Therapeutics. J.K. Botson, MD, RPh, Orthopedic Physicians Alaska, Anchorage, Alaska; J.R. Tesser, MD, R. Bennett, MD, Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona; H.M. Kenney, MD, Arthritis Northwest, PLLC, Spokane, Washington; P.M. Peloso, MD, MSc, K. Obermeyer, MS, B. LaMoreaux, MD, MS, Horizon Therapeutics, Lake Forest, Illinois; M.E. Weinblatt, MD, Brigham and Women’s Hospital, Boston, Massachusetts; 6J. Peterson, MD, Western Washington Arthritis Clinic, Bothell, Washington, USA. JKB has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/ speaker fees > $10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. JRT has received research grants/support from Horizon. HMK has received research support from Horizon Therapeutics as a study site and principal investigator, and has served as a speaker. PMP, KO, and BL are employees of and own stock in Horizon Therapeutics. MEW has received grants from Amgen, Bristol Myers Squibb, Crescendo Bioscience, Lilly, and Sanofi; has received consulting fees > $10k from Bristol Myers Squibb, Corona, and Lilly and < 10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; and has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. JP has received research support from Horizon Therapeutics (study site/investigator), and has also served as an advisor and speaker for Horizon Therapeutics. RB has no financial relationships that pose a potential conflict of interest. Address correspondence to Dr. J.K. Botson, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508, USA. Email: jbotson@opaak.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted September 11, 2020.
John R.P. Tesser
This work was supported by Horizon Therapeutics. J.K. Botson, MD, RPh, Orthopedic Physicians Alaska, Anchorage, Alaska; J.R. Tesser, MD, R. Bennett, MD, Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona; H.M. Kenney, MD, Arthritis Northwest, PLLC, Spokane, Washington; P.M. Peloso, MD, MSc, K. Obermeyer, MS, B. LaMoreaux, MD, MS, Horizon Therapeutics, Lake Forest, Illinois; M.E. Weinblatt, MD, Brigham and Women’s Hospital, Boston, Massachusetts; 6J. Peterson, MD, Western Washington Arthritis Clinic, Bothell, Washington, USA. JKB has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/ speaker fees > $10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. JRT has received research grants/support from Horizon. HMK has received research support from Horizon Therapeutics as a study site and principal investigator, and has served as a speaker. PMP, KO, and BL are employees of and own stock in Horizon Therapeutics. MEW has received grants from Amgen, Bristol Myers Squibb, Crescendo Bioscience, Lilly, and Sanofi; has received consulting fees > $10k from Bristol Myers Squibb, Corona, and Lilly and < 10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; and has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. JP has received research support from Horizon Therapeutics (study site/investigator), and has also served as an advisor and speaker for Horizon Therapeutics. RB has no financial relationships that pose a potential conflict of interest. Address correspondence to Dr. J.K. Botson, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508, USA. Email: jbotson@opaak.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted September 11, 2020.
Ralph Bennett
This work was supported by Horizon Therapeutics. J.K. Botson, MD, RPh, Orthopedic Physicians Alaska, Anchorage, Alaska; J.R. Tesser, MD, R. Bennett, MD, Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona; H.M. Kenney, MD, Arthritis Northwest, PLLC, Spokane, Washington; P.M. Peloso, MD, MSc, K. Obermeyer, MS, B. LaMoreaux, MD, MS, Horizon Therapeutics, Lake Forest, Illinois; M.E. Weinblatt, MD, Brigham and Women’s Hospital, Boston, Massachusetts; 6J. Peterson, MD, Western Washington Arthritis Clinic, Bothell, Washington, USA. JKB has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/ speaker fees > $10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. JRT has received research grants/support from Horizon. HMK has received research support from Horizon Therapeutics as a study site and principal investigator, and has served as a speaker. PMP, KO, and BL are employees of and own stock in Horizon Therapeutics. MEW has received grants from Amgen, Bristol Myers Squibb, Crescendo Bioscience, Lilly, and Sanofi; has received consulting fees > $10k from Bristol Myers Squibb, Corona, and Lilly and < 10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; and has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. JP has received research support from Horizon Therapeutics (study site/investigator), and has also served as an advisor and speaker for Horizon Therapeutics. RB has no financial relationships that pose a potential conflict of interest. Address correspondence to Dr. J.K. Botson, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508, USA. Email: jbotson@opaak.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted September 11, 2020.
Howard M. Kenney
This work was supported by Horizon Therapeutics. J.K. Botson, MD, RPh, Orthopedic Physicians Alaska, Anchorage, Alaska; J.R. Tesser, MD, R. Bennett, MD, Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona; H.M. Kenney, MD, Arthritis Northwest, PLLC, Spokane, Washington; P.M. Peloso, MD, MSc, K. Obermeyer, MS, B. LaMoreaux, MD, MS, Horizon Therapeutics, Lake Forest, Illinois; M.E. Weinblatt, MD, Brigham and Women’s Hospital, Boston, Massachusetts; 6J. Peterson, MD, Western Washington Arthritis Clinic, Bothell, Washington, USA. JKB has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/ speaker fees > $10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. JRT has received research grants/support from Horizon. HMK has received research support from Horizon Therapeutics as a study site and principal investigator, and has served as a speaker. PMP, KO, and BL are employees of and own stock in Horizon Therapeutics. MEW has received grants from Amgen, Bristol Myers Squibb, Crescendo Bioscience, Lilly, and Sanofi; has received consulting fees > $10k from Bristol Myers Squibb, Corona, and Lilly and < 10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; and has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. JP has received research support from Horizon Therapeutics (study site/investigator), and has also served as an advisor and speaker for Horizon Therapeutics. RB has no financial relationships that pose a potential conflict of interest. Address correspondence to Dr. J.K. Botson, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508, USA. Email: jbotson@opaak.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted September 11, 2020.
Paul M. Peloso
This work was supported by Horizon Therapeutics. J.K. Botson, MD, RPh, Orthopedic Physicians Alaska, Anchorage, Alaska; J.R. Tesser, MD, R. Bennett, MD, Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona; H.M. Kenney, MD, Arthritis Northwest, PLLC, Spokane, Washington; P.M. Peloso, MD, MSc, K. Obermeyer, MS, B. LaMoreaux, MD, MS, Horizon Therapeutics, Lake Forest, Illinois; M.E. Weinblatt, MD, Brigham and Women’s Hospital, Boston, Massachusetts; 6J. Peterson, MD, Western Washington Arthritis Clinic, Bothell, Washington, USA. JKB has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/ speaker fees > $10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. JRT has received research grants/support from Horizon. HMK has received research support from Horizon Therapeutics as a study site and principal investigator, and has served as a speaker. PMP, KO, and BL are employees of and own stock in Horizon Therapeutics. MEW has received grants from Amgen, Bristol Myers Squibb, Crescendo Bioscience, Lilly, and Sanofi; has received consulting fees > $10k from Bristol Myers Squibb, Corona, and Lilly and < 10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; and has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. JP has received research support from Horizon Therapeutics (study site/investigator), and has also served as an advisor and speaker for Horizon Therapeutics. RB has no financial relationships that pose a potential conflict of interest. Address correspondence to Dr. J.K. Botson, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508, USA. Email: jbotson@opaak.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted September 11, 2020.
Katie Obermeyer
This work was supported by Horizon Therapeutics. J.K. Botson, MD, RPh, Orthopedic Physicians Alaska, Anchorage, Alaska; J.R. Tesser, MD, R. Bennett, MD, Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona; H.M. Kenney, MD, Arthritis Northwest, PLLC, Spokane, Washington; P.M. Peloso, MD, MSc, K. Obermeyer, MS, B. LaMoreaux, MD, MS, Horizon Therapeutics, Lake Forest, Illinois; M.E. Weinblatt, MD, Brigham and Women’s Hospital, Boston, Massachusetts; 6J. Peterson, MD, Western Washington Arthritis Clinic, Bothell, Washington, USA. JKB has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/ speaker fees > $10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. JRT has received research grants/support from Horizon. HMK has received research support from Horizon Therapeutics as a study site and principal investigator, and has served as a speaker. PMP, KO, and BL are employees of and own stock in Horizon Therapeutics. MEW has received grants from Amgen, Bristol Myers Squibb, Crescendo Bioscience, Lilly, and Sanofi; has received consulting fees > $10k from Bristol Myers Squibb, Corona, and Lilly and < 10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; and has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. JP has received research support from Horizon Therapeutics (study site/investigator), and has also served as an advisor and speaker for Horizon Therapeutics. RB has no financial relationships that pose a potential conflict of interest. Address correspondence to Dr. J.K. Botson, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508, USA. Email: jbotson@opaak.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted September 11, 2020.
Brian LaMoreaux
This work was supported by Horizon Therapeutics. J.K. Botson, MD, RPh, Orthopedic Physicians Alaska, Anchorage, Alaska; J.R. Tesser, MD, R. Bennett, MD, Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona; H.M. Kenney, MD, Arthritis Northwest, PLLC, Spokane, Washington; P.M. Peloso, MD, MSc, K. Obermeyer, MS, B. LaMoreaux, MD, MS, Horizon Therapeutics, Lake Forest, Illinois; M.E. Weinblatt, MD, Brigham and Women’s Hospital, Boston, Massachusetts; 6J. Peterson, MD, Western Washington Arthritis Clinic, Bothell, Washington, USA. JKB has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/ speaker fees > $10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. JRT has received research grants/support from Horizon. HMK has received research support from Horizon Therapeutics as a study site and principal investigator, and has served as a speaker. PMP, KO, and BL are employees of and own stock in Horizon Therapeutics. MEW has received grants from Amgen, Bristol Myers Squibb, Crescendo Bioscience, Lilly, and Sanofi; has received consulting fees > $10k from Bristol Myers Squibb, Corona, and Lilly and < 10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; and has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. JP has received research support from Horizon Therapeutics (study site/investigator), and has also served as an advisor and speaker for Horizon Therapeutics. RB has no financial relationships that pose a potential conflict of interest. Address correspondence to Dr. J.K. Botson, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508, USA. Email: jbotson@opaak.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted September 11, 2020.
Michael E. Weinblatt
This work was supported by Horizon Therapeutics. J.K. Botson, MD, RPh, Orthopedic Physicians Alaska, Anchorage, Alaska; J.R. Tesser, MD, R. Bennett, MD, Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona; H.M. Kenney, MD, Arthritis Northwest, PLLC, Spokane, Washington; P.M. Peloso, MD, MSc, K. Obermeyer, MS, B. LaMoreaux, MD, MS, Horizon Therapeutics, Lake Forest, Illinois; M.E. Weinblatt, MD, Brigham and Women’s Hospital, Boston, Massachusetts; 6J. Peterson, MD, Western Washington Arthritis Clinic, Bothell, Washington, USA. JKB has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/ speaker fees > $10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. JRT has received research grants/support from Horizon. HMK has received research support from Horizon Therapeutics as a study site and principal investigator, and has served as a speaker. PMP, KO, and BL are employees of and own stock in Horizon Therapeutics. MEW has received grants from Amgen, Bristol Myers Squibb, Crescendo Bioscience, Lilly, and Sanofi; has received consulting fees > $10k from Bristol Myers Squibb, Corona, and Lilly and < 10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; and has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. JP has received research support from Horizon Therapeutics (study site/investigator), and has also served as an advisor and speaker for Horizon Therapeutics. RB has no financial relationships that pose a potential conflict of interest. Address correspondence to Dr. J.K. Botson, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508, USA. Email: jbotson@opaak.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted September 11, 2020.
Jeff Peterson
This work was supported by Horizon Therapeutics. J.K. Botson, MD, RPh, Orthopedic Physicians Alaska, Anchorage, Alaska; J.R. Tesser, MD, R. Bennett, MD, Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona; H.M. Kenney, MD, Arthritis Northwest, PLLC, Spokane, Washington; P.M. Peloso, MD, MSc, K. Obermeyer, MS, B. LaMoreaux, MD, MS, Horizon Therapeutics, Lake Forest, Illinois; M.E. Weinblatt, MD, Brigham and Women’s Hospital, Boston, Massachusetts; 6J. Peterson, MD, Western Washington Arthritis Clinic, Bothell, Washington, USA. JKB has received research support from Horizon Therapeutics and Radius Health as a study site and principal investigator. He has received consulting/ speaker fees > $10k from Horizon Therapeutics, Celgene, Novartis, and AbbVie. JRT has received research grants/support from Horizon. HMK has received research support from Horizon Therapeutics as a study site and principal investigator, and has served as a speaker. PMP, KO, and BL are employees of and own stock in Horizon Therapeutics. MEW has received grants from Amgen, Bristol Myers Squibb, Crescendo Bioscience, Lilly, and Sanofi; has received consulting fees > $10k from Bristol Myers Squibb, Corona, and Lilly and < 10k from AbbVie, Amgen, Arena, GlaxoSmithKline, Gilead Sciences, Horizon Therapeutics, Lycera, Novartis, Pfizer, Roche, Samsung, Scipher Medicine, and Set Point; and has stock options in Lycera, Can-Fite BioPharma, Scipher Medicine, Inmedix, and Vorso. JP has received research support from Horizon Therapeutics (study site/investigator), and has also served as an advisor and speaker for Horizon Therapeutics. RB has no financial relationships that pose a potential conflict of interest. Address correspondence to Dr. J.K. Botson, Orthopedic Physicians Alaska, 3801 Lake Otis Parkway, Anchorage, AK 99508, USA. Email: jbotson@opaak.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted September 11, 2020.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR)
John K. Botson, John R.P. Tesser, Ralph Bennett, Howard M. Kenney, Paul M. Peloso, Katie Obermeyer, Brian LaMoreaux, Michael E. Weinblatt, Jeff Peterson
The Journal of Rheumatology Sep 2020, jrheum.200460; DOI: 10.3899/jrheum.200460
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR)
John K. Botson, John R.P. Tesser, Ralph Bennett, Howard M. Kenney, Paul M. Peloso, Katie Obermeyer, Brian LaMoreaux, Michael E. Weinblatt, Jeff Peterson
The Journal of Rheumatology Sep 2020, jrheum.200460; DOI: 10.3899/jrheum.200460